Matches in SemOpenAlex for { <https://semopenalex.org/work/W47280155> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W47280155 endingPage "5" @default.
- W47280155 startingPage "852" @default.
- W47280155 abstract "To study blood concentrations of methotrexate (MTX) in Uyghur and Han children with acute lymphoblastic leukemia (ALL), and to provide criteria for judging the incidence of adverse effects of MTX.Twenty-eight children with ALL (15 Han children and 13 Uyghur children), who received high-dose MTX chemotherapy, were divided into >10 μmol/L and ≤10 μmol/L groups according to 24-hour blood concentration of MTX, and divided into >1.0 μmol/L and ≤1.0 μmol/L groups according to 48-hour blood concentration of MTX. Enzyme multiplied immunoassay was used to measure blood concentrations of MTX in the MTX-treated children at 24 and 48 hours after MTX administration, and the adverse effects were observed.There was no significant difference in the incidence of adverse effects between the >10 μmol/L and ≤10 μmol/L groups (P>0.05). The >1.0 μmol/L group showed higher incidences of gastrointestinal reactions and mucosal injuries than the ≤1.0 μmol/L group (P<0.05), but no significant difference was found between the two groups with respect to the incidence of abnormal liver function and bone marrow suppression (P>0.05). Compared with Uyghur children, Han children showed higher 24- and 48-hour blood concentrations of MTX (P<0.05) and higher incidence of abnormal liver function, mucosal injuries, and bone marrow suppression (P<0.05).The 24-hour blood concentration of MTX cannot be used to predict the incidence of adverse effects in MTX chemotherapy, but 48-hour blood concentration of MTX is helpful in this regard. There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy. Monitoring of blood MTX concentration maybe significant for timely adjustment of MTX dosage and individualized MTX chemotherapy." @default.
- W47280155 created "2016-06-24" @default.
- W47280155 creator A5026693129 @default.
- W47280155 creator A5029599797 @default.
- W47280155 creator A5067212641 @default.
- W47280155 date "2012-11-01" @default.
- W47280155 modified "2023-09-23" @default.
- W47280155 title "[Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children]." @default.
- W47280155 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23146734" @default.
- W47280155 hasPublicationYear "2012" @default.
- W47280155 type Work @default.
- W47280155 sameAs 47280155 @default.
- W47280155 citedByCount "0" @default.
- W47280155 crossrefType "journal-article" @default.
- W47280155 hasAuthorship W47280155A5026693129 @default.
- W47280155 hasAuthorship W47280155A5029599797 @default.
- W47280155 hasAuthorship W47280155A5067212641 @default.
- W47280155 hasConcept C120665830 @default.
- W47280155 hasConcept C121332964 @default.
- W47280155 hasConcept C126322002 @default.
- W47280155 hasConcept C197934379 @default.
- W47280155 hasConcept C2776581026 @default.
- W47280155 hasConcept C2776694085 @default.
- W47280155 hasConcept C2778461978 @default.
- W47280155 hasConcept C2780007613 @default.
- W47280155 hasConcept C2781059491 @default.
- W47280155 hasConcept C2909962599 @default.
- W47280155 hasConcept C2992208098 @default.
- W47280155 hasConcept C3020359197 @default.
- W47280155 hasConcept C61511704 @default.
- W47280155 hasConcept C71924100 @default.
- W47280155 hasConcept C90924648 @default.
- W47280155 hasConceptScore W47280155C120665830 @default.
- W47280155 hasConceptScore W47280155C121332964 @default.
- W47280155 hasConceptScore W47280155C126322002 @default.
- W47280155 hasConceptScore W47280155C197934379 @default.
- W47280155 hasConceptScore W47280155C2776581026 @default.
- W47280155 hasConceptScore W47280155C2776694085 @default.
- W47280155 hasConceptScore W47280155C2778461978 @default.
- W47280155 hasConceptScore W47280155C2780007613 @default.
- W47280155 hasConceptScore W47280155C2781059491 @default.
- W47280155 hasConceptScore W47280155C2909962599 @default.
- W47280155 hasConceptScore W47280155C2992208098 @default.
- W47280155 hasConceptScore W47280155C3020359197 @default.
- W47280155 hasConceptScore W47280155C61511704 @default.
- W47280155 hasConceptScore W47280155C71924100 @default.
- W47280155 hasConceptScore W47280155C90924648 @default.
- W47280155 hasIssue "11" @default.
- W47280155 hasLocation W472801551 @default.
- W47280155 hasOpenAccess W47280155 @default.
- W47280155 hasPrimaryLocation W472801551 @default.
- W47280155 hasRelatedWork W2330937224 @default.
- W47280155 hasRelatedWork W2351874472 @default.
- W47280155 hasRelatedWork W2360175764 @default.
- W47280155 hasRelatedWork W2374692110 @default.
- W47280155 hasRelatedWork W2377386508 @default.
- W47280155 hasRelatedWork W2378048842 @default.
- W47280155 hasRelatedWork W2381187499 @default.
- W47280155 hasRelatedWork W2388709023 @default.
- W47280155 hasRelatedWork W2390528363 @default.
- W47280155 hasRelatedWork W47280155 @default.
- W47280155 hasVolume "14" @default.
- W47280155 isParatext "false" @default.
- W47280155 isRetracted "false" @default.
- W47280155 magId "47280155" @default.
- W47280155 workType "article" @default.